Shares of Mesoblast Limited (MESO) touched a new 52-week high of $12.70 yesterday, as the company awaits the FDA decision on Ryoncil in the proposed indication of pediatric steroid-refractory acute graft versus host disease.
Ryoncil, also known as Remestemcel-L, comprises of culture-expanded mesenchymal stromal cells derived from the bone marrow of an unrelated donor. It is administered to patients in a series of intravenous infusions.
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.